1. SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.
- Author
-
Hoff, Fieke W., Goksu, Suleyman Y., Premnath, Naveen, Patel, Prapti A., Ikpefan, Ruth, Kaur, Gurbakhash, Vusirikala, Madhuri, Bat, Taha, Weina Chen, Geethakumari, Praveen Ramakrishnan, Anderson Jr., Larry D., Awan, Farrukh T., Collins, Robert H., Weinberg, Olga K., Muthukumar, Alagarraju, Chung, Stephen S., and Madanat, Yazan F.
- Subjects
- *
HEMATOLOGIC malignancies , *ANTIBODY formation , *COVID-19 vaccines , *SARS-CoV-2 , *IMMUNOGLOBULIN G - Abstract
Objective. Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies. Methods. Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer. Results. Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine. Conclusion. Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF